Silence Therapeutics

SLN | NASDAQ

Price Alert Chart Builder DCF Calculator

$12.25

+$0.05 (+0.41%)

At close: Sep 21, 2026, 4:00 PM ET

$12.29

+$0.04 (+0.33%)

Pre-market: Sep 22, 2026, 4:42 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $578.62M

Enterprise Value $506.45M

Beta 1.41

Average Volume 761.84K

Shares Outstanding (Diluted) 47.24M

Shares Change YoY 200.03%

Institutional Ownership N/A

Exchange NASDAQ

ISIN US82686Q1013

Price Performance

Price Change 1M -9.3%

Price Change 3M 68.5%

Price Change 6M 124.0%

Price Change YTD 99.2%

Price Change 1Y 143.1%

Price Change 3Y 14.1%

Price Change 5Y -43.8%

1M CAGR (ann.) 2.5%

1Y CAGR (ann.) 143.5%

5Y CAGR (ann.) -11.4%

All-Time CAGR -7.4%

Valuation

PE Ratio -5.59

Forward PE N/A

PEG Ratio -0.24

Forward PEG -0.16

PS Ratio 941.92

Forward PS 460.30

PB Ratio 15.04

P/FCF Ratio -13.66

P/Adj. FCF Ratio -10.35

P/OCF Ratio -4.55

EV/Sales 824.44

EV/EBIT -8.33

EV/EBITDA -8.40

EV/FCF -11.96

Earnings Yield -17.9%

FCF Yield -7.3%

Adj. FCF Yield -9.7%

Financial Health

Net Cash $72.17M

Total Debt $-112K

Cash & Short-Term Investments $72.05M

Total Assets $106.41M

Current Ratio 7.42

Quick Ratio 7.42

Debt / Equity Ratio 0.00

Debt / EBITDA 0.00

Debt / FCF 0.00

OCF / Debt 377.56

Interest Coverage 0.00

Altman Z-Score -3.61

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 51.0%

Operating Profit Margin -10880.3%

EBITDA Margin -9814.0%

Net Profit Margin -9759.2%

FCF Margin -6893.2%

Adj. FCF Margin -9101.3%

SBC / Revenue 2208.1%

SBC Impact (per share) -32.0%

Returns

Return on Assets -56.3%

Return on Equity -106.9%

Return on Invested Capital -71.3%

Return on Capital Employed -71.3%

Return on Tangible Assets -62.5%

Historical Growth (CAGR)

Revenue CAGR 3Y -72.2%

Revenue CAGR 5Y -43.0%

Revenue CAGR 10Y 21.6%

EPS CAGR 3Y 9.8%

EPS CAGR 5Y -3.4%

EPS CAGR 10Y -21.8%

FCF CAGR 3Y -11.1%

FCF CAGR 5Y -11.4%

FCF CAGR 10Y -23.9%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 5

EPS Growth Next 3Y 23.9%

Revenue Growth Next 3Y 11.4%

Earnings Date Nov 4, 2026

EPS Estimate (next Q) -$0.12

EPS Growth Est (next Q) -74.0%

Revenue Est (next Q) $124.22K

Revenue Growth Est (next Q) -21.9%

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $57

Price Target Upside 365.3%

Cash Flow

Operating Cash Flow $-42.29M

Free Cash Flow $-42.34M

Adj. Free Cash Flow $-55.91M

FCF Per Share -$2.69

OCF Per Share -$2.69

OCF/S Ratio -6883.8%

Income Statement

Revenue $614.29K

Gross Profit $313.29K

Operating Income $-66.84M

EBITDA $-60.29M

Net Income $-59.95M

EPS (Diluted) -$2.19

Revenue / Employee $6.98K

Profit / Employee $-681.25K

Employees 88